BioSpace News Archive

Portage Biotech Inc. today announced that Dr. Ian Walters, Chief Executive Officer of Portage, will be appointed Chairman of Portage’s Board of Directors.

Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the management team of Intercept will participate in B. Riley’s PBC (Primary Biliary Cholangitis) Mini Symposium: Orphan Liver Disease That May Not Be As Rare As You’d Think.

Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today announced the successful completion of safety measures for their Phase I Multi-Day Ascending Dosing (MAD) clinical trial. Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects.

Ybrain recently received the Translational Research Award at this year’s Neuroergonomics Conference and NYC Neuromodulation Conference held from July 28 to August 1 for its neuromodulation technology in transcranial direct current stimulation (tDCS).

Odylia Therapeutics today announced the appointments of Sharon M. Walker , Ph.D., J.D., and Brian Fenton to its Board of Directors.

Valo Health, Inc. today announced that dosing has commenced in its Phase 2 study - a multi-center randomized, double-blind, placebo-controlled study to evaluate safety and efficacy of oral OPL-0401 in patients with mild, moderate, and severe non-proliferative diabetic retinopathy (NPDR).

Bayer, a leader in women’s healthcare, announced today that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) that extends the duration of use for its market leading intrauterine device (IUD) Mirena® (levonorgestrel-releasing intrauterine system) 52 mg by one more year, making it available to prevent pregnancy for up to eight years.

Stramsen Biotech Inc. is a Houston, Texas -based Biotechnology Company that currently has eleven new natural plant-based drug candidates for clinical development.

Rentschler Biopharma, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced the appointment of Mark Caswell as Vice President, Site Head.

Rocket VR Health, a digital therapeutics company developing immersive therapy programs, is partnering with Penn Medicine’s Abramson Cancer Center to explore the use of virtual reality (VR) technology in cancer patients undergoing radiation therapy.